Company profile

George A. Scangos
Incorporated in
Fiscal year end
IRS number

VIR stock data

FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors


19 Nov 19
24 Feb 20
31 Dec 20


28.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 38 0 +Infinity%
Opened positions 38 0 +Infinity%
Closed positions 0 0 NaN%
Increased positions 0 0 NaN%
Reduced positions 0 0 NaN%
13F shares
Current Prev Q Change
Total value 397.06M 0 +Infinity%
Total shares 31.57M 0 +Infinity%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
SB Investment Advisers 22.62M $284.41M NEW
Temasek 5.5M $69.16M NEW
Capital International Investors 983.3K $12.37M NEW
Indus Capital Partners 681.94K $8.58M NEW
Baillie Gifford & Co 500K $6.29M NEW
BLK BlackRock 277.05K $3.49M NEW
ICONIQ Capital 250K $3.14M NEW
Vanguard 169.87K $2.14M NEW
NTRS Northern Trust 105.75K $1.33M NEW
JPM JPMorgan Chase & Co. 99.74K $1.26M NEW
Largest transactions
Shares Bought/sold Change
SB Investment Advisers 22.62M +22.62M NEW
Temasek 5.5M +5.5M NEW
Capital International Investors 983.3K +983.3K NEW
Indus Capital Partners 681.94K +681.94K NEW
Baillie Gifford & Co 500K +500K NEW
BLK BlackRock 277.05K +277.05K NEW
ICONIQ Capital 250K +250K NEW
Vanguard 169.87K +169.87K NEW
NTRS Northern Trust 105.75K +105.75K NEW
JPM JPMorgan Chase & Co. 99.74K +99.74K NEW

Financial report summary

  • We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve or maintain profitability.
  • Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
  • Even after IPO, we will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.
  • Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.
  • The development of additional product candidates is risky and uncertain, and we can provide no assurances that we will be able to replicate our approach for other diseases.
  • Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals.
  • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.
  • Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates.
  • If the market opportunities for our product candidates are smaller than we believe they are or any approval we obtain is based on a narrower definition of the patient population, our business may suffer.
  • We face substantial competition, which may result in others developing or commercializing products before or more successfully than us.
  • Even if any product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
  • Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval outside the United States, which would limit our market opportunities.
  • Negative developments and negative public opinion of new technologies on which we rely may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
  • Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.
  • If any of our future small molecule product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of affected products.
  • Any biologic, or large molecule, product candidates for which we intend to seek approval may face competition sooner than anticipated.
  • Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell profitably, if approved.
  • Healthcare legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects.
  • We are subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.
  • We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.
  • Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.
  • If we breach our license agreements or any of the other agreements under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the ability to continue the development and commercialization of the related product candidates.
  • If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.
  • Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
  • Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.
  • We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.
  • Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.
  • We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
  • Intellectual property rights do not necessarily address all potential threats to our business.
  • We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.
  • We have in the past and may in the future acquire or invest in other companies or technologies, which could divert our management’s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our internal computer systems, or those of our collaborators, service providers or other contractors or consultants, may fail or suffer security breaches, which could result in a significant disruption of our product development programs and our ability to operate our business effectively, and adversely affect our business, financial condition, results of operations and prospects.
  • We receive, process, store and use personal information and other data, which subjects us to governmental regulation and other legal obligations, liability and risks related to privacy, security, and data protection, and our actual or perceived failure to comply with such obligations could harm our business.
  • The Tax Cuts and Jobs Act, or the Tax Act, could adversely affect our business and financial condition.
  • Our ability to use our NOLs to offset future taxable income may be subject to certain limitations.
  • Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.
  • The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
  • Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.
  • If research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
  • Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.
  • A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is performing well.
  • As a public company, we are now subject to more stringent federal and state law requirements.
  • We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.
  • Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.
  • Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Management Discussion
  • Total revenue was $1.4 million and $2.9 million for the three months ended September 30, 2019 and 2018, respectively and $7.1 million and $7.5 million for the nine months ended September 30, 2019 and 2018, respectively. The decrease in total revenue for the three months ended September 30, 2019 was primarily due to a decrease in revenue recognized under the Campylo/EPEC/EAEC grant with the Bill & Melinda Gates Foundation, which expired in May 2019, and the HIV and TB grants with the Bill & Melinda Gates Foundation due to timing of research activities under these grants. The decrease in total revenue for the nine months ended September 30, 2019 was primarily due to a decrease in contract revenue recognized for research and development services.
Content analysis ?
H.S. junior Avg


No filings